Deal Watch: Gilead Grows Oncology, Inflammation Pipeline With XinThera Buy
Syneos Purchased For $7.1bn In Go-Private Deal
Executive Summary
The XinThera deal gives Gilead multiple PARP1 and MK2 inhibitors. Also, Roche licenses a HER2 kinase inhibitor from Zion, Amgen partners with TScan in Crohn’s disease and Baxter sells the last of its biopharma operations – a CDMO business – for $4.5bn.
You may also be interested in...
FibroGen Misses In First Of Two Pivotal DMD Trials
The biotech’s pamrevlumab fails a Phase III study in non-ambulatory Duchenne muscular dystrophy, but the antibody still has a shot in ambulatory DMD, as well as IPF and pancreatic cancer.
Sobi Set To Grow Hematology Franchise With $1.7bn CTI Biopharma Buy
Sobi plans to capitalize on the complimentary expertise at CTI Biopharma to together boost sales of the latter firm’s myelofibrosis drug Vonjo and enhance the Swedish pharma firm’s overall growth.
Bayer Saddles Up For Bicycle Radioconjugate Pact
The German major is paying $45m upfront to get access to Bicycle’s synthetic peptides for the discovery and development of multiple targeted radioconjugates in oncology.